Thursday, May 22, 2014

Wall Street Journal Reports Collaboration between DaVita Clinical Research, Aethlon Medical and Stephen Fadem

Aethlon Medical announces definitive agreement with DaVita Clinical Research, selecting DaVita Medical Center as their study site and Stephen Fadem as their principal investigator.

Here are Steve Fadem's comments:

We will be studying the Aethlon Hemopurifier®, a novel therapeutic device that targets the rapid elimination of viruses like hepatitis C and the tumor-secreted exosomes that can suppress the immune system in cancer patients.

Exosomes are vesicles created by the cell that can fuse with the cell wall membrane leading to the release of waste products. These products can be used as biomarkers for disease. However, the cell seems to use them for sending signals between cells or for waste management. Since the excreted exosomes can transfer "cargo" of molecules that may suppress the immune system, they may allow pathogens and tumors to adapt and grow. They may enhance angiogenesis and metastasis. Efforts are underway to further study the role of exosomes in disease pathogenesis. Meanwhile, we are collaborating with Athleon and DaVita Clinical Research to find ways to remove viral particles and ultimately exosomes from the circulation.

2 comments:

  1. Great blog thanks for share amazing information relate to kidneys health.

    ReplyDelete
  2. Thanks a lot for sharing detailed article! really an amazing post. You might also be interested to know more about our company. narwhal data partners helps you achieve your business goals through customized database, connect with interested qualified prospects who are seeking information to move forward in the buying process.Kidney Dialysis & Transplantation Services Email List



    ReplyDelete